-
Regulatory research on IDE exemptions: A case study in persistence (part 1)
A client presented us with a simple question – Do we need to submit an Investigational Device...
-
Science of Patient Input (SPI): Part 3
Patient input into study design – participation considerations. The last, in a series about the science of...
-
Science of Patient Input (SPI): Part 2
Last time we discussed how patients’ opinions can shape the design of a clinical study by altering...
-
Science of Patient Input (SPI): Part 1
The first of three, in a series about the science of patient input. It is tempting to...
-
Inclusion/Exclusion Criteria development
There is frequently confusion about what items should be listed as inclusion criteria and what should be...
-
Honoring Ours and Serving Others
On August 31st, 2018 MED Institute celebrated another year of honoring employees at the annual awards banquet....
-
Clinical Trials for Medical Device Innovators Part V: Important Points
The fifth and final, in a blog series about clinical trials for medical device innovators. Read part...
-
Cost Drivers for Clinical Trials: Clinical Trials for Medical Device Innovators Part IV
Cost Drivers for Clinical Trials: Clinical Trials for Medical Device Innovators Part IV. The fourth, in a...
-
IHIF Annual Gala Dinner
On September 13th, MED had the opportunity to be a sponsor at the 2017 IHIF Annual Gala...
-
The medical device product lifecycle is challenging. We can help you through all of the steps!
MED recently exhibited at MD&M West in Anaheim, CA. We were so excited to begin the trade show...
-
MedTech Policy Forum
On September 20th Justin Renfrow, Director of Business Operations, participated in the 2016 MedTech Policy Forum. This...
-
MD&M Minneapolis 2016
We ended our 2016 tradeshow season in Minneapolis, MN at MD&M Minneapolis – September 21 and 22nd....
OUR COMMITMENT
We are committed to consistently performing services with high quality, that deliver exceptional results, and add value to the client’s business.
For client surveys sent in the last two quarters, we received ratings of 4.98/5 points (9).